Definition‐specific prevalence estimates for sarcopenia in an Australian population: the Geelong Osteoporosis Study. Issue 4 (3rd July 2020)

• Record Type: Journal Article
• Authors: Sui, Sophia X.; Holloway‐Kew, Kara L.; Hyde, Natalie K.; Williams, Lana J.; Tembo, Monica C.; Leach, Sarah; Pasco, Julie A.
• Is Part Of: JCSM clinical reports. Volume 5:Issue 4(2020)
• Page Start: 89
• Page End: 98
• Publication Date: 2020-07-03
• Subjects: Sarcopenia definitions -- Sarcopenia prevalence -- Muscle mass -- Muscle strength -- Muscle function -- Aged; Cachexia -- Periodicals; Muscles -- Aging -- Periodicals; Muscles -- Diseases -- Periodicals; Cachexia; Sarcopenia; Muscular Diseases; Muscles -- physiology; Electronic journals; Periodicals; Periodical; 616.74
• DOI: 10.1002/crt2.22
• Languages: English
• ISSNs: 2521-3555

Abstract

Abstract: Background: We aimed to compare prevalence estimates for sarcopenia in an Australian sample of older men and women by using different criteria. Methods: Women ( n = 323) and men ( n = 342) aged 60–96 years from the Geelong Osteoporosis Study were included. Handgrip strength (HGS) was measured by dynamometer (Jamar or Vernier) and appendicular lean mass (ALM) by whole‐body densitometry (Lunar). Sarcopenia definitions included European Working Group on Sarcopenia in Older People (EWGSOP) 1, EWGSOP2, and US Foundation for the National Institutes of Health (FNIH). Sarcopenia was identified as low HGS and low ALM/height 2 or low muscle performance, and low HGS and low ALM/body mass index (BMI). Prevalence estimates were standardized to the Australian population and agreement between definitions assessed using the Cohen kappa statistic ( κ ). Results: Low HGS was identified in 13.7–29.9% of women and 2.1–14.1% of men. Low ALM/height 2 was identified in 7.1–11.8% of women and 6.0–8.4% of men, while 21.7% of women and 21.1% of men had low ALM/BMI. Mean age‐standardized prevalence estimates for sarcopenia were 5.9% (95% confidence interval 3.4–8.4) for women and 2.9% (1.9–4.0) for men (EWGSOP1), 2.3% (1.1–3.4) for women and 0.5% (0.2–0.9) for men (EWGSOP2), and 4.0% (2.1–5.8) for women and 1.1% (0.6–1.5) for men (FNIH). There was moderate agreement between EWGSOP1 and EWGSOP2 ( κ = 0.58 women, 0.30 men) and poor agreement between FNIH and EWGSOP1 ( κ = 0.16 women, 0.12 men) and EWGSOP2 ( κ = 0.19 women, 0 men). Conclusions: Sarcopenia prevalence differed according to definition applied. Point estimates for sarcopenia prevalence according to EWGSOP2 identified fewer individuals than EWGSOP1, with FNIH estimates between the two; however, there were overlapping 95% confidence intervals across definitions.